Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.51B |
| Gross Profit (TTM) | $1.16B |
| EBITDA | $953.01M |
| Operating Margin | 49.00% |
| Return on Equity | 99.40% |
| Return on Assets | 22.10% |
| Revenue/Share (TTM) | $12.72 |
| Book Value | $1.85 |
| Price-to-Book | 44.02 |
| Price-to-Sales (TTM) | 6.56 |
| EV/Revenue | 7.62 |
| EV/EBITDA | 18.43 |
| Quarterly Earnings Growth (YoY) | 31.20% |
| Quarterly Revenue Growth (YoY) | 42.20% |
| Shares Outstanding | $118.61M |
| Float | $117.25M |
| % Insiders | 1.06% |
| % Institutions | 108.30% |
Volatility is currently contracting
Halozyme (HALO) has delivered ~134% price appreciation since my prior 'Buy' rating in 06/2023. I evaluate whether HALO can sustain its strong growth trajectory or is due for a period of consolidation. The investment thesis centers on HALO's robust royalty revenue and product income as key growth drivers.
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading. Halozyme will host a conference call on Thursday, August 6, 2026 at 1:30pm PT/4:30pm ET to discuss the results.
Halozyme Therapeutics, Inc. (HALO) shares gain 539% since first Big Money outlier inflow signal in March 2014.
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focus on the potential for ENHANZE® to strengthen the subcutaneous formulation currently in development for INCA033989, with the goal of enabling more convenient delivery and dosing regimens that may improve the treatment experience.
ARCO, HALO, TX and ARRY screen as high-earnings-yield value picks as the Middle-East conflict sharpens stock selection.
SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026. In this newly created role, Mr.
SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on June 12, 2026. "Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035.
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to HALO stock based on the movements in the options market lately.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HALO and any ticker you trade — then tracks every position and per-strategy win rate.
